Chronic Lymphocytic Leucemia Completed Phase 2 Trials for Obinutuzumab (DB08935)

IndicationStatusPhase
DBCOND0074005 (Chronic Lymphocytic Leucemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02345863Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL PatientsTreatment